-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On December 28, Eisai and Biogen announced that lecanemab, an investigational anti-amyloid beta (Aβ) fibril antibody for the treatment of early Alzheimer's disease (AD), has been approved by the U.
In September 2021, Eisai began rolling submissions of a Biologics License Application (BLA) for lecanemab to the FDA under the accelerated approval pathway
A Phase 3 clinical study of lecanemab Clarity AD in early AD is ongoing and completed enrollment in March 2021 with a total of 1,795 patients
Note: The original text has been deleted